An Open Phase I Single Dose Escalation Study of BI 2536 BS Administered Intravenously in Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma.

Trial Profile

An Open Phase I Single Dose Escalation Study of BI 2536 BS Administered Intravenously in Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma.

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Oct 2013

At a glance

  • Drugs BI 2536 (Primary)
  • Indications Anaplastic large cell lymphoma; B cell lymphoma; Burkitt's lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Peripheral T-cell lymphoma; T cell lymphoma
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 04 Jun 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Jun 2012 Actual end date (1 Aug 2008) added as reported by ClinicalTrials.gov.
    • 28 Jul 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top